Selank: The Calm-Without-Sedation Peptide — With a Single-Region Evidence Problem

The short version

Selank is a synthetic heptapeptide built from an endogenous immune-signaling tetrapeptide called tuftsin, extended at the C-terminus with Pro-Gly-Pro to slow enzymatic breakdown. The full sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics in Moscow and is registered in Russia as a prescription anxiolytic nasal spray.

Of the three peptides on this desk, Selank has the most human data. A small Russian clinical study in patients with generalized anxiety disorder found anxiolytic effects comparable to a benzodiazepine comparator, without sedation, cognitive impairment, or withdrawal ^[11]. That is a meaningful result — and it is the kind of result that requires independent replication in Western populations before it can be stated without qualification. That replication does not yet exist. Outside Russia, Selank is sold strictly as a research chemical and is not approved for human use by the FDA or EMA. This page describes the evidence it has, and the evidence it lacks.

What it is

Selank is the synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, also known as TP-7 or simply the Selank heptapeptide. It is derived from tuftsin (Thr-Lys-Pro-Arg), an endogenous tetrapeptide fragment of the IgG heavy chain that has immunomodulatory and some behavioral-activating properties. The C-terminal Pro-Gly-Pro tail — the same element added to Semax — slows enzymatic hydrolysis in plasma, extending the peptide's effective half-life. As a tuftsin analog, Selank carries an immunomodulatory heritage that goes beyond a simple anxiolytic mechanism, which creates a distinct set of interaction unknowns.

How it works

Selank's anxiolytic and nootropic effects are attributed to two primary, non-benzodiazepine mechanisms. First, it acts as a positive allosteric modulator of GABA receptor binding — a 2018 molecular review established that Selank modulates [³H]GABA binding in a subtype-selective, concentration-dependent manner that differs from benzodiazepines, and can even block the modulatory activity of diazepam and olanzapine, indicating distinct but overlapping binding sites ^[6]. Second, it inhibits enkephalin-degrading enzymes (enkephalinases) in human plasma in vitro with an IC50 of approximately 15 micromolar ^[12], stabilizing endogenous enkephalins and engaging the opioid-linked anti-anxiety system.

Beyond these two main axes, Selank shifts expression of GABAergic neurotransmission genes in rat frontal cortex: 45 genes were significantly changed at 1 hour after administration and 22 at 3 hours, with changes correlating positively with those produced by GABA itself ^[8]. It also increases BDNF expression in the rat hippocampus ^[9] and modulates Th1/Th2 cytokine balance in patients with anxiety-asthenic disorders ^[10]. The interaction with the diazepam-plus-Selank combination (most effective intervention in a rat UCMS stress model ^[7]) confirms GABAergic interaction, though whether this translates to favorable or risky human combination effects is not characterized.

What the research shows

GABAergic mechanism. The foundational 2018 molecular review established Selank as a positive allosteric GABA-receptor modulator with subtype-selective concentration-dependent effects, blocking modulatory activity of diazepam — indicating it shares the GABA system without simply being a benzodiazepine mimic ^[6]. A rodent frontal-cortex gene-expression study confirmed a significant, GABA-correlated shift in 45 genes at 1 hour ^[8].

Diazepam interaction in stress. In rats under unpredictable chronic mild stress, the combination of diazepam with Selank was the most effective intervention — more effective than either alone — restoring behavior toward pre-stress levels ^[7]. That finding is mechanistically informative and a reason for caution about human combinations with GABAergic drugs.

BDNF regulation. Intranasal Selank increased BDNF expression in the rat hippocampus ^[9], linking it to the same neuroplasticity axis as Semax and providing a potential basis for the nootropic effects reported by users.

Enkephalinase inhibition. A human-plasma in vitro assay found dose-dependent inhibition of enkephalin-degrading enzyme activity with IC50 approximately 15 micromolar ^[12], supporting enkephalinase inhibition as a mechanism — consistent with the normalized enkephalin half-life hypothesis in generalized anxiety.

Immunomodulation in patients. In patients with anxiety-asthenic disorders, Selank shifted the Th1/Th2 cytokine balance and modulated IL-6 expression, characterizing it as an immunomodulator with properties beyond classical anxiolytics ^[10].

Human clinical evidence. A 2008 Russian clinical study in patients with generalized anxiety disorder found Selank produced anxiolytic and mild activating effects comparable to a benzodiazepine comparator, without sedation, cognitive impairment, or withdrawal — the most direct human evidence for any compound on this desk ^[11]. This was conducted at a Russian institution, is reported in a Russian-language journal with an English abstract, and has not been independently replicated in a Western RCT.

Reported effects, cautions & safety

The following are drawn from nootropic forums, peptide-user community guides, and biohacker writeups. They are anecdotal, not clinical evidence, and are kept entirely separate from the cited research findings above.

The single most consistent community report is a softening of background anxiety without sedation — the volume on anxious thoughts being turned down while mental energy holds steady. It is frequently and explicitly contrasted with the foggy heaviness of benzodiazepines or the emotional flatness of SSRIs. Very commonly, people use it situationally — before a presentation, exam, or difficult conversation — and report markedly fewer nerves with a heart rate that stayed low and a mind that stayed clear. Fast onset when used intranasally (roughly 20-40 minutes) is commonly noted. A calm-but-sharp focus quality — concentration improving once anxious mental chatter quiets — is a frequent companion to the anxiety relief. A gradual mood lift and baseline stress resilience over one to two weeks of regular use is commonly described as a cumulative effect. Non-response is a real and commonly voiced part of the picture: many users describe finishing a vial and feeling nothing, or being unsure the effect was real. Short single-dose duration is a common practical complaint. A minority report mild tiredness, over-calm, or mental softness, especially with frequent or heavy use. Nasal irritation with intranasal use is common.

From the cited literature, the key cautions are:

• Single-region evidence base. The great majority of studies originate from a small set of Russian institutions. Independent Western replication is limited, and many key papers are available only in Russian-language journals ^[11].
• Interaction unknowns from multiple active systems. Selank touches GABAergic, opioid, monoaminergic, and immune signaling ^{[6][7][12][10]}. The potential for additive or unpredictable interactions with medications acting on those same systems is real and essentially unstudied in Western populations.
• Immune-signaling activity is a distinct unknown. As a tuftsin analog, Selank shifts cytokine balance ^[10]. The downstream consequences of nudging immune signaling are not characterized in long-term human use.
• Self-treating anxiety with an investigational compound delays real care. Anxiety that is persistent or impairing has established, evidence-based treatments. Even the Russian trials were conducted under medical supervision in diagnosed patients.
• Not FDA- or EMA-approved. Selank is sold strictly as a research chemical outside Russia. It is not intended for human consumption.

Where it fits in cognitive research

Selank is the lead compound on this desk precisely because it has the most human data — a small Russian clinical trial in generalized anxiety disorder with a real comparator and a real outcome ^[11]. That is more than most research peptides can say. It is also honestly less than what Western medicine requires before calling something evidence-based. Its anxiety angle is distinct from Semax's cognitive-activation angle and from DSIP's sleep angle, giving the three peptides genuine complementarity. Read alongside Semax for the neurotrophin and focus story, and DSIP for the sleep end of the neuroactive spectrum. The comparison page lines them up side by side.